PeptiDream and Takeda expand deal
The Japanese pairing of PeptiDream (TYO: 4587) and Takeda (TYO: 4502) have announced an expansion of their research collaboration and exclusive license agreement to create peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets.
They originally entered into a collaborative research and exclusive license agreement in December 2020 to create PDCs for neuromuscular diseases by conjugating peptides developed by PeptiDream and JCR Pharmaceuticals (TYO: 4552) that bind to human transferrin receptor 1 (TfR1) to specific drug payloads selected by Takeda.
"PeptiDream’s TfR1 binding technology holds great promise for tackling the biodistribution challenges needed to develop effective therapies for complex neurological disorders"This new collaboration expands the use of the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration, allowing Takeda to conjugate the peptides with therapeutic cargoes optimized to cross the blood-brain barrier (BBB).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze